Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Cassava Sciences Inc (FLNA) Price & Performance

Vanguard Total Bond Market Index Fund ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Vanguard Total Bond Market Index Fund ETF vs Cassava Sciences Inc — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.7, while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). Which is the better fit depends on your goals.

BNDFLNA
52-Week High
$75.17$4.64
52-Week Low
$72.45$1.09
Market Cap
$52.66M
Sector
Health
Enterprise Value
-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total Bond Market Index Fund ETF

BND trades at $72.50, down 0.37% with a bearish technical outlook showing 19 sell signals versus 4 buy signals. The ETF faces pressure from rising interest rate expectations, though recent dividend payments of $0.24-$0.25 provide income stability. Fixed income ETFs have seen renewed investor interest with $100 billion flowing into cash ETFs recently, indicating defensive positioning.

The bond ETF faces headwinds from potential Fed rate hikes but offers diversification benefits. Key risks include interest rate sensitivity and competition from higher-yielding alternatives. Long-term investors may find value in BND's broad market exposure and low costs despite near-term technical weakness.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total Bond Market Index Fund ETF

This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.

Read more on BND

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA